1. Management Strategies for CLN2 Disease
Ruth E. Williams, DM, FRCPCH, Heather R. Adams, PhD, Martin Blohm, MD, Jessica L. Cohen-Pfeffer, MD, Emily de los Reyes, MD, Jonas Denecke, MD, Kristen Drago, RN, CHPPN, Charlie Fairhurst, MBBS, FRCPCH, Margie Frazier, PhD, Norberto Guelbert, MD, PhD, Szilárd Kiss, MD, Annamaria Kofler, PT, John A. Lawson, BMed, FRACP, PhD, Lenora Lehwald, MD, Mary-Anne Leung, SRD, Svetlana Mikhaylova, MD, Jonathan W. Mink, MD, PhD, Miriam Nickel, MD, Renée Shediac, PhD, Katherine Sims, MD, Nicola Specchio, MD, PhD, Meral Topcu, MD, Ina von Löbbecke, PT, Andrea West, MSc, Boris Zernikow, MD, PhD, Angela Schulz, MD, PhD 
Pediatric Neurology 
Volume 69, Pages (April 2017)
DOI: /j.pediatrneurol
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
A palliative care framework for CLN2 disease management facilitates comprehensive care of patients and their families. (The color version of this figure is available in the online edition.)
Pediatric Neurology  , DOI: ( /j.pediatrneurol )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Goals evolve as CLN2 disease progresses. PPR, photoparoxysmal response; IPS, intermittent photic stimulation; EEG, electroencephalography; WM, white matter; MRI, magnetic resonance imaging. (The color version of this figure is available in the online edition.)
Pediatric Neurology  , DOI: ( /j.pediatrneurol )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Management strategies for CLN2 disease. (The color version of this figure is available in the online edition.)
Pediatric Neurology  , DOI: ( /j.pediatrneurol )
Copyright © 2017 The Authors Terms and Conditions